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Abstract
Background: Nearly 45% of people living at risk for lymphatic filariasis (LF) worldwide live in India. India has faced
challenges obtaining the needed levels of compliance with its mass drug administration (MDA) program to interrupt LF
transmission, which utilizes diethylcarbamazine (DEC) or DEC plus albendazole. Previously identified predictors of and
barriers to compliance with the MDA program were used to refine a pre-MDA educational campaign. The objectives of this
study were to assess the impact of these refinements and of a lymphedema morbidity management program on MDA
compliance.
Methods/Principal Findings: A randomized, 30-cluster survey was performed in each of 3 areas: the community-based pre-
MDA education plus community-based lymphedema management education (Com-MDA+LM) area, the community-based
pre-MDA education (Com-MDA) area, and the Indian standard pre-MDA education (MDA-only) area. Compliance with the
MDA program was 90.2% in Com-MDA+LM, 75.0% in Com-MDA, and 52.9% in the MDA-only areas (p,0.0001). Identified
barriers to adherence included: 1) fear of side effects and 2) lack of recognition of one’s personal benefit from adherence.
Multivariable predictors of adherence amenable to educational intervention were: 1) knowing about the MDA in advance of
its occurrence, 2) knowing everyone is at risk for LF, 3) knowing that the MDA was for LF, and 4) knowing at least one
component of the lymphedema management techniques taught in the lymphedema management program.
Conclusions/Significance: This study confirmed previously identified predictors of and barriers to compliance with India’s
MDA program for LF. More importantly, it showed that targeting these predictors and barriers in a timely and clear pre-MDA
educational campaign can increase compliance with MDA programs, and it demonstrated, for the first time, that
lymphedema management programs may also increase compliance with MDA programs.
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Introduction
There are 1.3 billion people living at risk of infection with the
parasites that cause lymphatic filariasis (LF) and an estimated 40
million suffering from the long-term complications of the disease
[1,2]. In 2000, the Global Programme for Elimination of LF
(GPELF) began its campaigns to interrupt transmission of the
parasite using a strategy of annual mass drug administration
(MDA) to those at risk and to control or prevent LF-related
disability through morbidity management programs [3].
India’s National Vector Borne Disease Control Programme has
scaled up MDA to interrupt LF transmission over the past several
years and recently began adding albendazole to diethylcarbama-
zine (DEC) therapy where available with the monumental goal of
providing mass drug treatment to all 590 million Indians living at
risk for infection [4]. Although the program has distributed
sufficient quantities of DEC tablets, problems have remained with
achieving sufficient levels of adherence to DEC regimens in many
regions in India [5–10], including Orissa State [11,12]. Published
estimates reporting drug coverage are often more accurately
characterized as estimates of drug distribution which overestimate
the actual drug consumption or compliance with MDA of the
population [6,13]. Mathematical models suggest interrupting
transmission is dependent on the baseline population prevalence
of LF infection and on overall population compliance with MDA
programs [14,15]. The lower the compliance with the MDA and
the higher the baseline prevalence of LF, the more rounds of MDA
required to interrupt transmission. Ensuring maximal compliance
is critical to programmatic success.
In some areas of India, the MDA program is restricted to tablet
distribution, and issues such as drug adherence, drug side effects,
and LF education of the populace are not comprehensively
addressed [13]. For this reason, in 2007 the Church’s Auxiliary for
Social Action (CASA) partnered with the Indian Ministry of
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Health in Orissa State to enhance adherence to the DEC regimen.
CASA developed a community-based educational campaign for
the populace in three sub-districts in Khurda District of Orissa
State. The campaign sought to increase awareness about the
occurrence of the MDA, about the transmission and prevention of
LF, about who should take DEC and the potential side effects, and
about mosquito control. The message was distributed over a four-
week period prior to the December 2007 MDA via radio and
newspaper advertisements, street plays, leaflet distributions,
broadcasting local songs incorporating health messages, posters,
wall paintings, and village educational sessions. CASA partnered
with the Centers for Disease Control and Prevention (CDC) to
evaluate the effectiveness of their program. This evaluation found
that adherence to the DEC regimen was less than 60% and failed
to detect a significant impact of the community-based education
campaign [16]. However, it identified barriers to and predictors of
adherence. The major barriers were fear of side effects and a lack
of recognition of the benefit of adherence. A model of predictors of
adherence to the DEC regimen found that people who knew about
the MDA in advance of its occurrence, people who knew that the
MDA was for LF prevention, and people who knew that
mosquitoes transmit LF were significantly more likely to adhere
to the medication. The model also suggested that those who knew
everyone was at risk for LF were also more likely to adhere, though
this was not statistically significant. Other studies have found
similar barriers and predictors using a variety of methodologies
[5,9,11,12,17–21], though relatively few provided a quantitative
measure of association [22,23].
Based on these data, the CASA community-based educational
message was refined to focus on these predictors and barriers. For
the December 2008 MDA, CASA expanded its community-based
educational campaign adding three new sub-districts to the
original three in Khurda District. These new sub-districts received
the same educational campaign described for the 2007 pre-MDA
campaign, but the educational messages incorporated these
refinements. Additionally, in early 2008, CASA initiated a
lymphedema management program which included both a
community-based education component for the entire populace
and patient self-care component focused on foot and leg hygiene
for affected individuals and their families. This program was
initiated in the three original sub-districts only.
This evaluation was designed with the following objectives: 1) to
assess the effectiveness of community-based LF education and
community-based lymphedema management education in in-
creasing compliance with the MDA program and 2) to validate the
importance of predictors of and barriers to adherence to the DEC
regimen identified in the previous evaluation.
Methods
Ethics Statement
The program was approved by the National Center for
Zoonotic, Vector-borne, and Enteric Diseases (NCZVED) Human
Subjects Committee at CDC, Atlanta, Georgia, USA, prior to the
implementation of the survey. Permission for the survey was
obtained from the Orissa State Department of Health and Family
Welfare. Participants were asked to give their written consent prior
to participation. For those unable to write, consent was
documented by recording the person’s fingerprint or marking
the signature line with an ‘X’ and by countersignature of survey
personnel. Consent procedures were approved by the Human
Subjects Committee.
Study Design
The 2008 MDA for Orissa occurred from December 28th to 30th.
The coverage survey occurred from February 19th to 28th, 2009. A
random 90-cluster sample design was utilized, with 30 villages
selected in each of three areas: the community-based pre-MDA
education plus community-based lymphedema management edu-
cation (Com-MDA+LM) area, the community-based pre-MDA
education (Com-MDA) area, and the Indian standard pre-MDA
education (MDA-only) area. The Com-MDA+LM area included
the three original sub-districts_Khurda, Balianta, and Balipat-
na_that received both the community-based pre-MDA educational
campaign and the community-based lymphedema management
program. The Com-MDA areas included the three new sub-
districts_Bologarh, Begunia, and Jatni_that received only the pre-
MDA educational campaign. The MDA-only area was composed of
one sub-district_Banapur_which did not border any of the other six
sub-districts and received only the standard Indian Ministry of
Health MDA campaign. Villages were selected in each area using
probability proportionate to size methodology [24,25]. In villages
with hamlets, which are areas of a village separate from the main
village, probability proportionate to size methodology was used to
determine whether the hamlet or the main village was sampled.
Fifteen households were randomly selected using the Expanded
Programme on Immunization (EPI) random walk methodology
[24]. Two quantitative surveys were performed: a household (HH)
survey, in which every member of the household was included, and
a knowledge, attitudes, and practices (KAP) survey, in which one
person in each household over the age of 17 was randomly chosen to
participate. Replacement of non-responders was not permitted.
The survey was designed to detect a difference in drug adherence
of 15% between the areas. Calculations were adjusted to allow for
two 2-way comparisons and to account for a design effect of 12,
based on the design effect found in the 2008 study [16]. Thus the
study had 80% power to detect 15% difference with an alpha of
0.025 if 3,181 persons were enrolled in each study area.
Analysis
Data were entered into EpiInfo v3.5.1 (Stone Mountain, GA)
and analysis was performed in SAS v9.2 (Cary, NC). All results
Author Summary
Global elimination of lymphatic filariasis requires giving
drugs at least annually to populations who live at risk of
becoming infected with the parasite. At least 80% of
people at risk need to take the drugs annually for 5 or
more years to stop transmission of the infection. People
suffering from the long-term effects of infection, such as
swollen legs, benefit from programs that teach self-care of
their affected limbs. In this study, we assessed the impact
of an educational campaign that, after addressing
previously identified predictors of compliance, significantly
improved drug compliance. The specific factors improving
compliance included knowing about the drug distribution
in advance, knowing that everyone is at risk for acquiring
the infection, knowing that the drug distribution was for
lymphatic filariasis prevention, and knowing at least one
component of leg care. We also found that areas with
programs to assist people with swollen legs had greater
increases in compliance. This research provides evidence
that program evaluation can be used to improve drug
compliance. In addition, our work shows for the first time
that programs to benefit people with swollen legs caused
by lymphatic filariasis also increase the participation of
people without disease in drug treatment programs.
Increasing Compliance with MDA in India
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presented from the HH and KAP surveys were adjusted for
stratification and clustering, except for tests for medians. All KAP
survey results were also weighted by the size of the eligible
population in the household. For differences between the three
areas, dichotomous variables were evaluated using chi-square tests
or Rao-Scott Likelihood Ratio Tests and continuous variables
were evaluated using tests for medians. Multivariable logistic
regression analysis of KAP data was performed to assess predictors
of adherence to DEC. All predictors that were statistically
significant (p#0.05) in univariable analysis were included in the
final model. Any demographic variable not found to be a
univariable predictor of adherence but which differed across the
three groups was included in the initial model. Interaction terms
were created and removed by examining the Wald chi-squares for
the individual components of the interaction terms. After
evaluation of the interaction terms, demographic variables that
were not found to be predictors of adherence were removed if
removal did not change the adjusted odds ratios (OR) for the
major predictors by at least 10% and if removal improved the
precision of the estimates for the major predictors. The model was
adjusted for weighting, clustering, and stratification.
Results
Household Survey
In Com-MDA+LM areas 449 (99.7%) households participated
in the HH survey, in Com-MDA areas 427 (94.9%) participated,
and in MDA-only areas 409 (90.9%) participated. There were
2949, 2863, and 2481 persons included in the survey, respectively.
The groups were similar in age distribution (median 29 years,
range 0.1 years–105 years), and sex distribution (52.0% male).
Tablets were received by 2784 (94.4%), 2671 (93.3%) and 2105
(84.9%) persons, respectively (p,0.0001). There were three
(0.1%), 67 (2.3%) and 49 (2.0%) persons eliminated from further
analysis because they did not live in the respective area at the time
of the MDA.
Adherence to the DEC regimen differed significantly between
the three areas (Table 1), with 90.2% adherence in Com-
MDA+LM areas, 75.0% adherence in Com-MDA areas, and
52.9% adherence in MDA-only areas. Among those who took
DEC, 217 (3.6%) reported side effects, the most common of which
was headache (125, 2.1%). All three groups reported similar rates
of side effects (p = 0.2). No one required hospitalization for side
effects. Persons who did not take DEC were asked why. All reasons
provided by more than 5% of the population are shown in Table 1.
The most common reason given in all areas was fear of side effects,
though persons in the Com-MDA+LM area were the least likely to
give this reason. Com-MDA+LM persons were more likely to state
that they were sick at the time of the MDA, which is a legitimate
contraindication in the Indian program.
KAP Survey
In Com-MDA+LM areas 445 (98.9%) persons participated in
the KAP survey, in Com-MDA areas 423 (94.0%) participated,
and in MDA-only areas 401 (89.1%) participated. One Com-
MDA+LM person was eliminated from the analysis because her
answers could not be weighted. The demographic breakdown of
KAP participants is shown in Table 2. There were statistically
significant differences in the sex, age, caste, educational level, and
literacy level distributions between the three groups. Although
households reporting at least one household member with a
swollen leg ranged from 9.7% to 18.6% to 23.5%, this difference
was not statistically significant (p = 0.28 for overall comparison
across the three groups).
Participants who complied with the MDA program were asked
why they took DEC. The most common reasons given were as
follows: 1) to prevent LF (463, 48.0%), 2) because the MDA
distributor told me to take DEC (344, 32.9%), and 3) because a
family member told me to take DEC (211, 22.6%). Participants who
did not take DEC were asked to specify why and what they would
need to be told to change their minds. The top five reasons given
were as follows: 1) fear of side effects (80, 30.3%), 2) lack of trust of
DEC (45, 16.9%), 3) sick at the time of the MDA (29, 9.5%), 4) not
at home when DEC was distributed (25, 9.2%), and 5) not sick and
therefore DEC was not needed (25, 9%). They reported they would
comply if convinced that taking DEC would help them (151,
52.3%), if convinced that taking DEC would help their family (53,
17.3%), or if taught to manage side effects (22, 9.8%).
Participants were asked questions about their knowledge of LF,
MDA, and lymphedema management. Responses are shown in
Table 1. Household survey: Rates of adherence and non-adherence to a DEC regimen and reasons for non-adherence during the
2008 MDA, Khurda District, Orissa State.
Category Com-MDA+LMa n (%) Com-MDAb n (%) MDA-onlyc n (%) p-value 1d p-value 2e
Adhered to DEC 2658 (90.2) 2097 (75.0) 1285 (52.9) ,0.0001 ,0.0001
Did not adhere to DEC 288 (9.8) 698 (25.0) 1146 (47.1)
Top reasons for non-adherence:
Fear of side effects 22 (17.6) 258 (45.3) 263 (32.3) 0.0008 0.07
Lack of trust of DEC 12 (9.6) 53 (9.3) 183 (22.5) 0.98 0.1
Not present for DEC distribution 22 (17.6) 136 (23.9) 48 (5.9) 0.4 ,0.0001
Forgot to take DEC 5 (4.0) 22 (3.9) 136 (16.7) 0.95 ,0.0001
DEC not needed/not sick 13 (10.4) 64 (11.2) 56 (6.9) 0.85 0.25
Sick when DEC given out 35 (28.0) 17 (3.0) 65 (8.0) ,0.0001 0.001
Note: A p-value #0.025 is considered statistically significant as a correction for multiple comparisons.
aCom-MDA+LM areas received community-based pre-MDA LF education and a community-based lymphedema management program.
bCom-MDA areas received community-based pre-MDA LF education.
cMDA-only areas received the Indian Ministry of Health MDA campaign.
dP-value 1 is for the comparison between Com-MDA+LM and Com-MDA.
eP-value 2 is for the comparison between Com-MDA and MDA-only.
doi:10.1371/journal.pntd.0000728.t001
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Table 3. Com-MDA+LM participants had greater knowledge
than Com-MDA participants that LF is transmitted by mosqui-
toes, everyone is at risk for LF, and there are specific treatments
for lymphedema such as leg exercises, leg washing, and leg
elevation. Com-MDA participants were much more likely than
MDA-only participants to know about the MDA in advance of its
occurrence, mosquitoes transmit LF, and antibiotics can be used
to help manage acute attacks. Com-MDA and MDA-only
participants were equally likely to know everyone was at risk
for LF.
Table 2. Demographics for KAP survey participants for the 2008 MDA, Khurda District, Orissa State.
Category Com-MDA+LMa n (%) Com-MDAb n (%) MDA-onlyc n (%) p-value overall
Male sex 217 (48.3) 172 (42.2) 145 (35.4) 0.009
Age, yearsd 30 (14–105) 35 (17–80) 34 (18–80) ,0.0001
Caste: 0.02
General castes 185 (44.9) 217 (49.4) 89 (21.6)
Backward castes 179 (40.1) 171 (43.2) 258 (67.4)
Scheduled castes & tribes 81 (11.2) 35 (7.4) 52 (10.8)
Education: ,0.0001
No schooling 6 (0.8) 33 (6.9) 85 (16.8)
Grades 1 to 5 111 (24.1) 151 (34.1) 157 (38.9)
Grades 6 to 10 247 (54.6) 187 (46.9) 106 (31.0)
Grades 11 to 12 44 (10.7) 36 (8.8) 18 (4.7)
Graduate and Post-graduate 36 (9.6) 16 (3.3) 32 (8.2)
Literacy: ,0.0001
Reads well 363 (83.5) 289 (68.3) 180 (52.7)
Reads with difficulty/not at all 79 (16.5) 134 (31.7) 201 (47.3)
Household member with swollen leg 89 (23.5) 75 (18.6) 40 (9.7) 0.28
Note: P-values derived from the Rao-Scott Likelihood Ratio Test except where noted.
aCom-MDA+LM areas received community-based pre-MDA LF education and a community-based lymphedema management program.
bCom-MDA areas received community-based pre-MDA LF education.
cMDA-only areas received the Indian Ministry of Health MDA campaign.
dMedian age (range), p-value for the difference in medians.
doi:10.1371/journal.pntd.0000728.t002
Table 3. Knowledge about LF and MDA among KAP survey participants from the 2008 MDA, Khurda District, Orissa State.
Com-MDA+LMa n (%) Com-MDAb n (%) MDA-onlyc n (%) p-value 1d p-value 2e
Knowledge item:
Knew about MDA in advance 425 (97.1) 387 (91.5) 257 (69.1) 0.03 ,0.0001
Knew MDA was for LF 439 (98.8) 386 (91.8) 368 (92.4) ,0.0001 0.82
Knew mosquitoes transmit LF 426 (95.7) 356 (84.0) 269 (68.9) ,0.0001 0.001
Thought contaminated water transmits LF 12 (2.7) 45 (12.4) 22 (4.9) ,0.0001 0.01
Knew everyone at risk for LF 403 (90.8) 208 (47.3) 173 (44.6) ,0.0001 0.67
Thought old people at risk for LF 16 (4.3) 136 (34.3) 162 (41.9) ,0.0001 0.22
Lymphedema treatments:
Antibiotics 211 (49.7) 153 (35.6) 41 (9.6) 0.05 ,0.0001
No treatment 63 (14.9) 93 (25.3) 152 (37.6) 0.06 0.07
Leg exercises 128 (30.8) 19 (5.3) 6 (1.6) ,0.0001 0.04
Leg washing 98 (21.6) 22 (5.5) 9 (2.8) ,0.0001 0.14
Leg elevation 31 (8.4) 6 (1.3) 3 (0.8) ,0.0001 0.52
Any of the 3 leg care answers 201 (46.3) 43 (11.3) 16 (4.6) ,0.0001 0.005
Note: Percentages are weighted. P-values derived from the Rao-Scott Likelihood Ratio Test. P-values #0.025 are significant.
aCom-MDA+LM areas received community-based pre-MDA LF education and a community-based lymphedema management program.
bCom-MDA areas received community-based pre-MDA LF education.
cMDA-only areas received the Indian Ministry of Health MDA campaign.
dP-value 1 is for the comparison between Com-MDA+LM and Com-MDA.
eP-value 2 is for the comparison between Com-MDA and MDA-only.
doi:10.1371/journal.pntd.0000728.t003
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Demographic and knowledge variables were examined to
determine if they were univariable predictors of adherence to
the DEC regimen. Results are shown in Table 4. Neither caste nor
male sex was a univariable predictor. Some quartiles of age,
having 11 to 12 years of education, reading well, and having a
household member with lymphedema were found to be predictors.
More importantly, five factors that could be addressed in
educational campaigns were found to predict adherence. They
are, in decreasing order of strength of association: knowing about
the MDA in advance of its occurrence (OR = 8.1; 95% CI: 5.2–
12.6), knowing the MDA was for LF (OR = 7.5; 95% CI: 4.3–
12.9), knowing one or more components of lymphedema
management (OR = 7.4; 95% CI: 3.8–14.6), knowing everyone
was at risk for LF (OR = 3.7; 95% CI: 2.5–5.3), and knowing
mosquitoes transmit LF (OR = 3.2; 95% CI: 2.2–4.7). Multivar-
iable modeling was then performed. A statistically significant
interaction between knowing about the MDA in advance of its
occurrence and knowing everyone was at risk for LF was found
and therefore was kept in the model. Male sex did not influence
the model and was removed. Caste, literacy, and having a
household member with lymphedema did not predict adherence
in multivariable analysis. Some quartiles of age and multiple
educational levels influenced adherence. Significant predictors,
which could be addressed in an educational campaign, included
knowing both about the MDA in advance and that everyone was
at risk for LF (adjusted OR = 16.1; 95% CI: 8.8–29.3), knowing
about the MDA in advance (adjusted OR = 4.8; 95% CI: 3.8–8.1),
knowing everyone was at risk for LF (adjusted OR = 2.2; 95% CI
Table 4. Univariable & multivariable analyses of predictors of adherence to a DEC regimen among KAP survey participants from
the 2008 MDA, Khurda District, Orissa State.
Variables Univariable analysis OR (95% CI) Multivariable analysis OR (95% CI)
Demographic variables:
Quartiles of age:
Age #25 years 1.7 (1.1–2.8) 1.8 (1.0–3.4)a
Age .25 & #35 years 1.3 (0.8–2.0) 1.3 (0.8–2.2)
Age .35 & #45 years 1.9 (1.2–3.1) 2.0 (1.2–3.2)
Age .45 years referent referent
Male sex 1.1 (0.8–1.6) †
Caste:
General castes referent referent
Backward castes 0.9 (0.5–1.4) 1.0 (0.6–1.4)
Scheduled castes & tribes 1.1 (0.5–2.5) 2.1 (0.9–4.8)
Education:
No school 0.6 (0.3–1.3) 3.5 (1.2–10.0)
Grades 1 to 5 1.3 (0.7–2.5) 3.2 (1.4–7.3)
Grades 6 to 10 1.7 (0.9–3.2) 2.0 (1.0–4.1)a
Grades 11 to 12 2.6 (1.1–6.2) 3.0 (1.0–8.7)a
Graduate or post-graduate referent referent
Literacy:
Reads well 2.1 (1.4–3.0) 1.6 (0.9–2.6)
Reads with difficulty/not at all referent Referent
Household member with leg edema 2.0 (1.2–3.3) 1.4 (0.8–2.4)
Knowledge variables:
Knew about MDA in advance 8.1 (5.2–12.6) †
Knew the MDA was for LF 7.5 (4.3–12.9) 3.3 (1.7–6.6)
Knew about lymphedema managementb 7.4 (3.8–14.6) 3.3 (1.6–6.9)
Knew everyone at risk for LF 3.7 (2.5–5.3) †
Knew mosquitoes transmit LF 3.2 (2.2–4.7) 1.3 (0.8–2.1)
Interaction between knew about MDA in
advance & knew everyone at risk for LF:
Knew both † 16.1 (8.8–29.3)
Only knew about MDA in advance † 4.8 (3.8–8.1)
Only knew everyone at risk for LF † 2.2 (1.0–4.8)c
Knew neither † Referent
aP-value = 0.05.
bKnew about lymphedema management means the participant could name at least one of the three components of lymphedema management: leg washing, leg
elevation, or leg exercises.
cP-value = 0.04.
doi:10.1371/journal.pntd.0000728.t004
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1.0–4.8; p = 0.04), knowing the MDA was for LF (adjusted
OR = 3.3; 95% CI: 1.7–6.6), and knowing at least one component
of lymphedema management self-care (adjusted OR = 3.3; 95%
CI: 1.6–6.9).
To further examine the impact of the lymphedema manage-
ment programs on adherence, two sub-analyses were performed.
In the first sub-analysis, the knowledge of univariable predictors of
adherence was compared between those who knew at least one of
the three components of lymphedema leg care and those who did
not know any. Only persons in Com-MDA+LM and Com-MDA
populations were included. As shown in Table 5, persons who
knew at least one component of leg care had greater knowledge of
all four of the univariable predictors of DEC adherence. The
second sub-analysis drew from this same population. Multivariable
analysis which included all predictors of adherence from the main
model was performed among those who had a household member
with leg swelling and among those who did not. Having knowledge
of at least one component of leg care predicted increased
adherence both among those who had a household member with
leg swelling (adjusted OR = 11.1, 95% CI: 1.4–86.1), and among
those without (adjusted OR = 5.1, 95% CI: 1.5–17.4).
Discussion
The evaluation of the December 2007 MDA in Orissa led to the
description of several predictors of and barriers to compliance with
the MDA program. These predictors and barriers were used to
refine a pre-MDA community-based educational campaign that
was then implemented in six blocks in Khurda District, three of
which had received the early version of the campaign_the Com-
MDA+LM area_and three of which were new to the campaign_-
the Com-MDA area. The results were remarkable. In the Com-
MDA+LM areas MDA compliance increased from a 2007
baseline of 59.5% [16] to 90.2%, well above that target of
80.0% compliance among the entire population. There was also a
marked increase in compliance in the Com-MDA areas to 75.0%,
which is close to the target and much improved from the 2007
baseline of 52.2% [16]. It is likely that the baseline MDA
compliance for rural areas in this district is around 52%, and it is
clear that both intervention groups had a significant increase in
adherence over that baseline.
This study not only makes an important and direct contribution
to the effort to interrupt the transmission of LF in India, it also
serves as an example that can be used by other programs to
overcome barriers to MDA compliance in affected populations.
The KAP survey allowed identification of predictors of and
barriers to adherence to a DEC regimen Factors identified in the
previous evaluation were targeted by an educational campaign
delivered one month prior to the 2008 MDA. The increased
adherence during the 2008 MDA campaign provided not only the
proof-of-concept that the targeted educational program worked,
but it also validated the previously identified predictors and
barriers. This assessment demonstrates how critical operational
research is to any health program, particularly one whose success
depends on changing health behaviors. Fortunately, this research
can lead to simple and effective solutions. Developing messages
that address key concepts for improving compliance with the
MDA program is essential. In Orissa, these include: 1) making
people aware of the occurrence of the MDA in advance of its
occurrence_the CASA program is launched one month prior to
the MDA, 2) making people aware of the purpose of the MDA
medication, 3) making people aware that everyone is at risk for
infection, 4) making people aware that one can be infected and still
feel well, and 5) making people aware that side effects of DEC are
infrequent and mild. Additionally, data from those who did not
take DEC suggested that the medication’s benefit needs to be
personalized. The person who takes the medication needs to feel
that they or a close family member stands to benefit directly. Lofty
national goals did not speak to those who did not take DEC in this
evaluation population. Individualized programs will need to be
developed to address the specific needs of each location.
One unique and important finding from the 2008 evaluation is
that community-based lymphedema management programs
positively affect MDA compliance independently of such pro-
grams’ effects on the other predictors of compliance. Even after
multivariable modeling controlling for all of the other LF and
MDA knowledge predictors, knowing any one of the three
components of the management of leg lymphedema predicted
adherence to the DEC regimen. This positive impact of
community-based lymphedema management education persisted
even among those who had no household members with
lymphedema. Additionally, the Com-MDA+LM area had the
highest level of persons adhering to the DEC regimen in this study
(90.2%). Admittedly, part of the explanation may be that the
Com-MDA+LM had received a pre-MDA educational campaign
two years in a row, but the campaign in the year 2007, which did
not focus on predictors of adherence, was largely ineffectual (as
evidenced by DEC adherence of 59.5% in the area in 2007).
Previous authors have suggested that morbidity control programs
could improve MDA compliance [3,26], but this study is the first
to provide data wholly consistent with, if not unequivocally
substantiating, that hypothesis. Perhaps these programs are
Table 5. Knowledge of univariable predictors of adherence to a DEC regimen among KAP participants from Com-MDA+LMa and
Com-MDAb areas: examining the difference in knowledge based on knowledge of lymphedema managementc.
Knowledge item Knew lymphedema management n (%) Did not know lymphedema management n (%) p-valued
Knew about MDA in advance 241 (99.5) 571 (92.4) ,0.0001
Knew MDA was for LF 239 (98.6) 586 (94.1) ,0.0001
Knew mosquitoes transmit LF 235 (96.6) 547 (87.3) ,0.0001
Knew everyone at risk for LF 214 (87.6) 397 (62.3) ,0.0001
aCom-MDA+LM areas received community-based pre-MDA LF education and a community-based lymphedema management program.
bCom-MDA areas received community-based pre-MDA LF education.
cA participant was considered as having knowledge of lymphedema management if the participant knew about at least one of the following: leg exercises, leg washing,
or leg elevation.
dP-values derived from the Rao-Scott Likelihood Ratio Test.
doi:10.1371/journal.pntd.0000728.t005
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effective because they help maintain awareness of LF and its
chronic manifestations in the community and reinforce LF
messages taught in the pre-MDA programs. Or perhaps they
enhance trust at the community and individual level by providing
programs benefiting a generally marginalized and stigmatized
population, those who suffer from lymphedema and elephantiasis.
Lymphedema management programs could provide an ideal
platform for both LF and MDA education to improve MDA
program compliance. As India approaches LF elimination, there
will be a continued need to assist LF patients with clinical disease.
Integrating lymphedema management with LF elimination efforts
could be a more cost-effective way to ensure that MDA
compliance remains high, even if political pressure to continue
funding elimination efforts diminishes.
There are several factors that could influence compliance that
merit further comment. Persons in the Com-MDA+LM areas had
the fewest number of people who reported no education and the
highest number who reported reading well. In univariable analysis
reading well influenced the decision to take DEC and education
level had relatively little impact on the decision; in multivariable
analysis the relationship reversed. Possibly the ability to weigh the
risks and benefits of MDA compliance is more directly related to
education level than to literacy. Additionally, the mechanisms
utilized to distribute the educational message included many
verbal routes (i.e. street plays, auto-rickshaws, etc). However, an
assessment of literacy, or health literacy, using a validated tool
might allow a more thorough examination of this complex
relationship. Multivariable analysis suggested that those with less
education were more likely to comply. Perhaps those with less
education are more likely to accept public health messages. It is
important to note that although the relationship with education
level is statistically significant, because of smaller numbers in each
group the confidence intervals around the ORs are wide and in
many cases approach one. It may be that the impact of education
on compliance is much less than suggested by our analysis; this is
an issue that should certainly be examined in future studies.
Knowing a household member with leg edema could also
influence one’s perception of risk for LF. While the prevalence of
leg edema in a household member did not differ statistically across
the three groups, the highest prevalence was reported in the Com-
MDA+LM group. Whether this represents actual increased
prevalence or increased recognition of the condition because of
the lymphedema management program is unclear. Even though
this factor was found to be a predictor of MDA compliance in
univariable analysis, it was not significant in multivariable analysis.
One possible reason for this is that the CASA educational message
emphasized that everyone was at risk for infection and that one
might be infected even if one felt well.
Finally, there was an interaction between knowing about the
MDA in advance and knowing everyone was at risk for LF. Those
who only knew everyone was at risk for LF had a small increase in
MDA compliance. Those who only knew about the MDA in
advance had a larger increase. Those who knew both had a
synergistically larger increase. Why this was so is not clear.
Perhaps those who understood both messages had a heightened
sense of benefit or felt more empowered to achieve their own
health goals because they felt at risk for infection and that they had
the opportunity to avail themselves of preventive medication.
Perhaps the interaction reflects the influence of another factor,
such as an understanding of side effects and their management. In
either case, the interaction points to the importance of addressing
risk of LF and opportunity to access the beneficial MDA
medication in any educational message.
The limitations of this evaluation are similar to other retrospective
evaluations that use the EPI random walk cluster method. Selection
bias was reduced by defining a strict set of rules governing household
selection and replacement of non-participants was not allowed. The
evaluation was cross-sectional, so causality cannot be assumed.
However, given that most of the predictors identified in this
evaluation were the same as in the prior evaluation and that the
knowledge of the predictors in the Com-MDA+LM area was higher
in this evaluation that in the prior one, it is likely that the predictors
are causal. The generalizability of the results may be limited to rural
areas as urban areas were not included. Finally, although there is a
definitive baseline MDA compliance for the Com-MDA+LM area,
the baseline for the Com-MDA and the MDA-only areas are based
on less direct empirical data. The Com-MDA baseline is derived
from the Bologarh MDA compliance of 52.2% for the 2007 MDA.
The fact that the compliance in Banapur for the 2008 MDA was
52.9% suggests that MDA compliance in rural areas of Khurda
District is approximately 50–55%.
Determining the predictors and barriers of adherence to the
DEC regimen distributed in the MDA allowed for identification of
key educational messages that were incorporated into a pre-MDA
community-based LF educational campaign and resulted in a
marked increase in regimen adherence. An added benefit was
demonstrating that community-based lymphedema management
programs independently enhanced adherence. Although further
work is needed to determine exactly which components of
lymphedema management programs influence MDA program
compliance, one should not wait for those results before investing
in such programs which address the twin goals of improving the
lives of those suffering from filarial disease and increasing
compliance with MDA programs to the level needed for the
interruption of LF transmission.
Supporting Information
Checklist S1 STROBE checklist.
Found at: doi:10.1371/journal.pntd.0000728.s001 (0.08 MB
DOC)
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